[Adrenergic receptor drugs in treatment of shock].
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D002395:Catecholamines / Q000378:metabolism; D002952:Citric Acid Cycle; D004357:Drug Synergism; D004877:Ergoloid Mesylates / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008680:Metaraminol / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010429:Pentoses / Q000378:metabolism; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011395:Promazine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013565:Sympatholytics / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D002395:Catecholamines; D010429:Pentoses; D013565:Sympatholytics; D013566:Sympathomimetics; D010643:Phenoxybenzamine; D004877:Ergoloid Mesylates; D008680:Metaraminol; D011433:Propranolol; D007545:Isoproterenol; D011395:Promazine; D009638:Norepinephrine; D010646:Phentolamine
Les médicaments des récepteurs adrénergiques dans le traitement du choc.